Long-term outcomes for esophageal cancer patients with complete response after neoadjuvant therapy
Part of Cancer, Digestive system clinical trials.
This study looks at patients with esophageal cancer who had a complete response to chemotherapy or radiation before surgery. It aims to understand how well these patients do over time, which could help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had chemotherapy or radiation before surgery for esophageal cancer between 2018 and 2023.
- You have a type of esophageal cancer called squamous cell carcinoma that is in the chest area.
- Your cancer was at a stage where it could be removed with surgery (not spread to distant organs).
- After surgery, tests showed no cancer cells left in the esophagus or lymph nodes (complete response).
- You did not have any other cancers in the past and do not have multiple cancers at the same time.
- You completed your planned neoadjuvant treatment and had standard surgery, not salvage surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses CT and MRI scans before and after chemotherapy or radiation to see how well the treatment worked in esophageal cancer. The goal is to match scan results with what doctors find after surgery.
This study looks at a specific marker in lymph nodes to predict whether PD-1 immunotherapy (a type of cancer-fighting immune treatment) will work well before surgery in esophageal cancer patients. Understanding this marker may help doctors choose the best treatment plan.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.